Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Viatris has been busy over the last year working to resolve FDA concerns at a critical drug manufacturing plant in India ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...

GenEdit is sailing toward the clinic with a new name and fresh funding.  | GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 ...

Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. | Novartis is wasting little time sketching out the radiopharmaceutical details ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD).

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase. | Sanofi has kicked off its preparations for the 2026 World ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...